000			01986 a2200601 4500
005			20250516133557.0
264		0	_c20131021
008			201310s 0 0 eng d
022			_a1476-5551
024	7		_a10.1038/leu.2013.38 _2doi
040			_aNLM _beng _cNLM
100	1		_aDeAngelo, D J
245	0	0	_aPhase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. _h[electronic resource]
260			_bLeukemia _cAug 2013
300			_a1628-36 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAcetylation
650	0	4	_aAdministration, Oral
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aDrug Administration Schedule
650	0	4	_aFemale
650	0	4	_aHematologic Neoplasms _xdiagnosis
650	0	4	_aHistone Deacetylase Inhibitors _xadministration & dosage
650	0	4	_aHistones _xmetabolism
650	0	4	_aHumans
650	0	4	_aHydroxamic Acids _xadministration & dosage
650	0	4	_aIndoles _xadministration & dosage
650	0	4	_aMale
650	0	4	_aMaximum Tolerated Dose
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Staging
650	0	4	_aPanobinostat
650	0	4	_aTreatment Outcome
650	0	4	_aYoung Adult
700	1		_aSpencer, A
700	1		_aBhalla, K N
700	1		_aPrince, H M
700	1		_aFischer, T
700	1		_aKindler, T
700	1		_aGiles, F J
700	1		_aScott, J W
700	1		_aParker, K
700	1		_aLiu, A
700	1		_aWoo, M
700	1		_aAtadja, P
700	1		_aMishra, K K
700	1		_aOttmann, O G
773	0		_tLeukemia _gvol. 27 _gno. 8 _gp. 1628-36
856	4	0	_uhttps://doi.org/10.1038/leu.2013.38 _zAvailable from publisher's website
999			_c22481329 _d22481329